Click image to enlargeA Phase 3, Randomized, Double-Blind, 52-Week, Placebo- Controlled, Efficacy, and Safety Study of Povorcitinib in Participants with Nonsegmental Vitiligo
Must be:
18 or older
Medically diagnosed with Nonsegmental vitiligo
Can not currently or have history of use of depigmenting agent monobenzyl ether of hydroquinone, such as Benoquin
Can not have any history of surgical treatment for vitiligo
Can not have currently have or had any history of the following
a. Thrombocytopenia, coagulopathy, or platelet dysfunction
b. Venous or arterial thrombosis, deep vein thrombosis, pulmonary embolism,
stroke, moderate to severe heart failure, myocardial infarction, or coronary
stunting
c. any diagnosis of other significant cardiovascular diseases
Can not have uncontrolled hypertension (defined as more than 160/100)
Can not have ever received an organ transplant
Can not currently or have history of HIV or an acquired immunodeficiency syndrome
Can not have any known hypersensitivity or severe reaction to Povorcitinib or to any other products in the same class
Must provide pictures of vitiligo to ensure screening eligibility